Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY: CYBN )

9.500 -0.030 (-0.31%)
Streaming Delayed Price Updated: 10:25 AM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
38 39 Next >
Major Investor Commits $30M To Psychedelics Funding
Canadian psychedelics biotech Cybin Inc. (NYSE: CYBN) entered into a common share purchase agreement with institutional investor Lincoln Park Capital Fund (LPC) for the sale of up to $30... 
Via Benzinga
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics... 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Common Stock Purchase Agreement Totaling $30M
Via Investor Brand Network
Topics Derivatives
Exposures Derivatives
Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund
From Cybin Inc.
Via Business Wire
Novel DMT Compound For Anxiety Shows Clinical Progress: Robust Effects Within 2 Minutes
Canadian clinical-stage psychedelics company Cybin Inc. (NYSE: CYBN) announced that the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Initiates Dosing of First Participants in Phase 1 Clinical Trial
Via Investor Brand Network
Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
From Cybin Inc.
Via Business Wire
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... 
Via Benzinga
Trial On DMT Drug For Anxiety And Depression Ends Participant Dosing, Study Results Soon Released
Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug... 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Doses Last Subject in Phase 1, Part B CYB004-E Trial
Via Investor Brand Network
Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial
From Cybin Inc.
Via Business Wire
April Psychedelic Drug Stocks Recap: The Ups And Downs
Via Talk Markets
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate at Upcoming Milken Institute Global Conference
Via Investor Brand Network
Cybin to Participate at the 26th Annual Milken Institute Global Conference
From Cybin Inc.
Via Business Wire
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
Via Benzinga
Cybin, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From April 18, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 17, 2023
Via Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules 
Via Benzinga
ATAI Life Sciences, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2023
Via Benzinga
EXCLUSIVE: Investing In The Unique Growth Market Of Psychedelics
The global psychedelics market of drugs such as psilocybin, ketamine and LSD is booming and there are plenty of ways to get involved in the space. 
Via Benzinga
Cybin Offers Free Online Training To Facilitate Psychedelic Therapy
Cybin Inc. (NYSE: CYBN), a clinical-stage biopharma company developing innovative psychedelic-based treatment options, is launching a free online facilitation training course. 
Via Benzinga
Psychedelic Stock Gainers And Losers From April 12, 2023
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Launches EMBARK OA, a Cost-Free Facilitator Training Program for Psychedelic Therapy
Via Investor Brand Network
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy
From Cybin Inc.
Via Business Wire
Psychedelic Stock Gainers And Losers From April 11, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 10, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From April 7, 2023
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.